Clinical Trial Update: Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating erlotinib with chemotherapy for unresectable or metastatic esophageal and gastric cardia adenocarcinoma completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastric Cardia Adenocarcinoma

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Translational Oncology Research International | Conditions: Unresectable Adenocarcinoma of the Esophagus, Metastatic Adenocarcinoma of the Esophagus | Phase 2 | Status: COMPLETED | Results posted: 2021-10-01